A comparative study of Xalatan and Xalacom (Pfizer, USA) efficacy in the treatment of pseudoexfoliative glaucoma

Cover Page

Abstract


The purpose of this study was to compare the efficacy of Xalatan (Pfizer, USA) and Xalacom (Pfizer, USA) in pseudoexfoliative glaucoma therapy. We observed 41 patients (53 eyes) with PEG, 16 of them were men and 25 women. Treatment period was 24 months. The main group (20 patients, 28 eyes) instilled Xalatan, the comparison group (21 patients, 25 eyes) instillated Xalacom once before bedtime (8 p. m.). In the Xalatan group, IOP decreased from 23.75 ± 0.576 mm Hg at baseline to 18.93 ± 0.337 mm Hg at 6 Month visit, and increased again up to 22.00 ± 0,542 mm Hg by the end of 24 months period. In the Xalacom group, IOP decreased from 22.00 ± 0.552 at baseline to 19.67 ± 0.47 at 6 Months visit and did not increase significantly to the 24 Month visit. Glaucoma stabilization was registered in both groups. MD index improved at 12 Months visit from –5.16 ± 0.61 to –4.21 ± 0.66, without significant changes till Visit 24 Month in the Xalatan group. MD index improved for the entire period of observation from –5.57 ± 0.64 to 4.82 ± 0.69 in the Xalatan group. These results allow us to recommend Xalatan and Xalacom as medications of choice for PEG treatment, especially taking into consideration possible risk of glaucomatous optic neuropathy progression.

Anastasiya Sergeevna Apostolova

FKU “The Main Bureau of Medico-social Examination across Krasnodar Krai” branch No. 7

Email: apostolovan@mail.ru
ophthalmologist

  1. Апостолова А. С., Волик Е. И., Климов С. В. Некоторые аспекты инвалидности по глаукоме в Краснодарском крае // Федоровские чтения — 2011: Всероссийская научно-практическая конференция с международным участием, IX: Сб. научных статей. — М., 2011. — С. 41
  2. Золотарев А. В. Карлова Е. В. О механизме действия фиксированной комбинации латанопроста и тимолола // Вопросы офтальмофармакологии. — 2011. — № 2. — С. 7175.
  3. Курышева Н.И., Деев А. И., Долгина Е. В. Псевдоэксофлиативная глаукома: особенности патогенеза и клинических проявлений // Глаукома: проблемы и решения. Всероссийская научно-практическая конференция — 2004. —С. 102–105
  4. Курышева Н.И., Ходак Н. А., Трубилин В. Н. Исследование нейропротекторного действия Ксалатана в клинике // Глаукома. —2008. — Т. 2. —С. 35–40
  5. Либман Е. С., Калеева Э. В., Рязанов Д. П. Комплексная характеристика инвалидности вследствие офтальмопаталогии в Российской Федерации // Федоровские чтения — 2011: Всероссийская научно-практическая конференция с международным участием, IX: Сб. научных статей. — М., 2011. — С. 45.
  6. Разумовский М. И. Коровянский М. С. Якунин М. С. Шевага А. Г. Динамика первичной инвалидности вследствие офтальмопатологии в Санкт-Петербурге, Ленинградской области и некоторых других регионах России за период с 2002–2008 гг. // Офтальмологические ведомости. — 2010. — Т. 3, № 4. — С. 4–15.
  7. Hartleben C., Ayala M., Chaves-Ayala R. et al. Morning vs evening use of Xalacom for primary open glaucoma // Book of abstracts World Glaucoma Congress. — Vienna, 2005. — P. 159.
  8. Konstas A. G., Boboridis K., Tzetzi D., Kallinderis K., Jenkins J. N., Stewart W. C. Twenty-four-hour control with latanoprost-timolol-fixed combination therapy vs latanoprost therapy // Arch Ophthalmol. — 200. Vol. 123, N 7. — P. 898–902.
  9. Konstas A., Hollo G., Akopov E., Teus M., Astakhov Y. Factors associated with long-term progression or stability in exfoliation glaucoma // Arch. Ophthalmol. — 2004. — Vol. 122, № 1. — P. 29–33.
  10. Konstas A., Mylopoulos N. Diurnal intraocular pressure reduction with latanoprost 0,005 % compared to timolol maleate 0,5 % as monotherapy in subjects with exfoliation glaucoma // Eye. — 2004. — Vol. 18, № 9. — P. 893–899.
  11. Konstas A., Koliakos G., Kanhardt as C, Liakos P., Schlotzer-Schrehaedt U., Ritch R. Latanoprost therapy reduces the levels of TGF beta 1 and gelatinases in the aqueous humor of patients with exfoliative glaucoma // Exp. Eye Res. — 2006. —Vol. 82, № 2. — P. 319–322.
  12. Konstas A., Kozobolis V. Efficacy and safety of latanoprost versus travaprost in exfoliative glaucoma patients // Ophthalmology. — 2007. — Vol. 114, № 4. — P. 653–657
  13. Larsson L.–I., Diestelhorst M. A 12-week, randomized, double–masked multicenter study of the fixed-combination Latanoprost and Timolol in the evening vs. the individual compoents // Book of abstracts World Glaucoma Congress. — Vienna, 2005. — P. 162.
  14. Liu Y., Schmidt S., Qin X., Gibson J. R., Hutchins K., Santiago-Turla C., Wiggs J. L., Budens D. L. et al. Lack of association between LOXL1variants and primary open-angle glaucoma in three different populations // Investing. Ophthalmol. Vis. Sci. — 2008. — Vol. 49. — Р. 3465–3468.
  15. Mishima H. K. et all. A comparison of Latanoprost and Timolol in primary open-angle glaucoma and ocular hypertension // Arch. Ophthalmology. — 1996. — Vol. 114. — P. 929–932.
  16. Orzalesi N., Rossetti L., Bottoli A., Fogagnolo P. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension // Ophthalmology. — 2006. — Vol. 113. — P. 239–246.
  17. Schlotzer-Schrebardt U., Zenkel M., Kuchle M. Role of transforming growth factor-β1 and its latent from binding protein in psevdoexfoliation syndrome // Exp. Eye res. — 2001. — Vol. 73. — P. 765–780.
  18. Schlotzer-Schrebardt U. Molecular pathology of psevdoexfoliation syndrome/glaucoma — New insights from LOXL1 gene associations // Exp. Exp. Eye res. — 2009. — Vol. 88. — P. 776–778.
  19. Ozkurt Y. B., Kurna S., Sengor T., Evciman T. Administration of the fixed combination of Latanoprost 0,005 % and Timolol 0,5 % in patients with over 30 mm Hg IOP // Book of abstracts 6th Claucoma symposium.– Athens, 2007. — P. 128.
  20. Zenkel M., Kruse F., Naumann G., Schlotzer-Schrebardt U. Impaired cellular stress response in eyes with psevdoexfoliation syndrome/glaucoma // Invest. Ophthalmol. Vis. Sci. — 2007. — Vol. 48. — P. 5558–5566.
  21. Zenkel M., Djordjevik-Jocic J., Lewczuk P. Matrix-metalloproteinases and their inhibitors in the aqueous humor of glaucoma patients: effect of antiglaucoma drugs // WOS-2010, Berlin, Abstract Book. — P-SU-098.

Views

Abstract - 3327

PDF (Russian) - 438

Cited-By


PlumX


Copyright (c) 2013 Apostolova A.S.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies